Aikvira Pharmaceuticals Private Limited has proudly introduced its latest offering, the "DCGI Approved – Polmacoxib Capsule," marking a significant advancement in the management of osteoarthritis (OA).

Osteoarthritis, commonly known as degenerative joint disease (DJD), affects numerous individuals, particularly in areas like the hands, hips, and knees. With OA, the deterioration of cartilage within the joints initiates changes in the underlying bone structure.

The Polmacoxib Capsule presents a novel nonsteroidal anti-inflammatory drug (NSAID) specifically designed for OA. Offering a swifter onset of relief compared to Celecoxib, it boasts improved gastrointestinal safety when juxtaposed with traditional NSAIDs. Additionally, it's formulated with potential cardiovascular safety measures to mitigate adverse effects.

The capsule's distinctive feature lies in its lowest daily dosage among all NSAIDs, ensuring effective management with minimal dosing. Moreover, Polmacoxib's efficacy has been demonstrated in clinical trials, showcasing superior results compared to placebo and non-inferiority to celecoxib over a six-week treatment period. Importantly, it is deemed safe for prolonged usage.

Aikvira Pharmaceuticals extends an invitation to collaborate on this groundbreaking product, alongside its existing range of pharmaceutical offerings. Customers are encouraged to reach out for further details or assistance.

The unveiling of Polmacoxib Capsule underscores Aikvira Pharmaceuticals' commitment to innovation in healthcare, promising enhanced treatment options for individuals battling osteoarthritis.